Health Catalyst Reports Second Quarter 2026 Results

Revenue fell 13% year-over-year despite beating guidance; losses remain high.

What the company is saying

Health Catalyst, Inc. frames the quarter as 'very productive,' highlighting that revenue and adjusted EBITDA exceeded guidance. The company emphasizes the closure of the Vitalware divestiture and full repayment of its credit facility debt, claiming these actions 'significantly improve' the balance sheet and enable strategic flexibility. Management asserts deep healthcare expertise and positions proprietary AI-driven technology as a driver of measurable outcomes, referencing $2.8 billion in 'documented outcomes' without providing supporting detail. Forward-looking guidance is provided for revenue and adjusted EBITDA, but not for net loss, with the rationale that certain items affecting net loss cannot be reasonably forecasted. The tone is neutral but leans promotional, with several claims about operational excellence and product impact presented as beliefs rather than substantiated facts. CEO Ben Albert is named, but no additional institutional signal is attached to his involvement.

What the data suggests

Total revenue for the quarter ended June 30, 2026, was $70,487,000, down 13% from $80,721,000 in the same quarter of 2025. Gross profit declined to $27,856,000 from $30,333,000, but gross margin improved to 40% from 38%. Net loss was $40,537,000, nearly unchanged from the prior year's $40,978,000. Adjusted EBITDA rose 6% to $9,919,000, indicating some improvement in non-GAAP profitability despite shrinking top-line. Cash and cash equivalents increased to $60,589,000 from $50,814,000 at year-end, and the company reports full repayment of its credit facility debt, though the balance sheet still shows $151,852,000 in long-term debt. No detailed evidence is provided for the $2.8 billion in 'documented outcomes.' The company does not reconcile adjusted EBITDA guidance to net loss, limiting transparency on future profitability. Overall, the numbers show deteriorating revenue and persistent losses, with only modest improvements in margin and adjusted EBITDA.

Analysis

The announcement presents a balanced tone, with factual disclosure of quarterly results and forward-looking guidance. The company exceeded revenue and adjusted EBITDA guidance for the quarter, which is supported by the disclosed numbers. However, the overall financial direction is negative, with a 13% year-over-year revenue decline and persistent net losses. Several claims about operational excellence and product impact are aspirational and lack supporting evidence or quantification. The statement about $2.8 billion in 'documented outcomes' is not substantiated with data or breakdowns. While the company highlights the closing of a divestiture and debt repayment, these are not directly tied to specific balance sheet figures in the disclosure. The hype level is moderate due to the use of promotional language and unsupported claims about product impact, but the presence of detailed financials and the absence of large, speculative capital outlays keep the hype score below high.

Risk flags

• ●Revenue declined 13% year-over-year, indicating customer or pricing pressure and raising questions about the sustainability of the business model. This matters because continued top-line contraction can undermine future profitability and cash flow.
• ●Net loss remains high at $40,537,000 for the quarter, showing that operational improvements have not translated into GAAP profitability. Persistent losses increase the risk of future dilution or the need for additional financing.
• ●Claims of balance sheet improvement and debt repayment are not fully supported by the disclosed numbers, as long-term debt remains at $151,852,000. This lack of direct reconciliation reduces confidence in the company's narrative about financial flexibility.
• ●Forward-looking claims about product impact and $2.8 billion in 'documented outcomes' are unsubstantiated by detailed evidence. Unsupported claims limit the credibility of management's assertions and make it difficult for investors to assess true value creation.

Bottom line

Health Catalyst, Inc.'s Q2 2026 results show a 13% year-over-year revenue decline and a net loss of $40.5 million, despite exceeding internal guidance for revenue and adjusted EBITDA. While gross margin and adjusted EBITDA improved, these gains are overshadowed by shrinking top-line and ongoing losses. Management's claims of balance sheet improvement and product-driven outcomes are not fully substantiated by the disclosed data, and long-term debt remains significant. Near-term guidance points to further revenue softness and minimal adjusted EBITDA, with no clear path to net profitability. For investors, the most important takeaway is that operational improvements have yet to reverse the company's negative financial trajectory. More granular disclosure on customer wins, segment performance, and the composition of 'documented outcomes' would be needed to reassess the investment case.

Announcement summary

(NASDAQ: HCAT) Health Catalyst, Inc. reported financial results for the quarter ended June 30, 2026, with total revenue of $70,487,000 and a net loss of $40,537,000. The company exceeded the high end of its revenue guidance and the midpoint of its adjusted EBITDA guidance for the second quarter. Gross profit for the quarter was $27,856,000, with a gross margin of 40%, and adjusted EBITDA was $9,919,000. Health Catalyst recently closed the Vitalware divestiture and fully repaid its credit facility debt. For the third quarter of 2026, the company expects total revenue of $55 million to $56 million and adjusted EBITDA of $0 to $0.5 million. For the full year 2026, Health Catalyst expects total revenue of $246 million to $249 million and adjusted EBITDA of $18 million to $18.5 million. As of June 30, 2026, cash and cash equivalents were $60,589,000, and total assets were $358,604,000.

Disagree with this article?